96 results about "Barr virus" patented technology

The present invention provides novel compositions comprising Epstein-Barr virus-specific oligonucleotides that are useful as primers to amplify particular regions of the genome during enzymatic nucleic acid amplification. The invention also provides a rapid, sensitive and specific method for the detection and quantitation of the virus which may be present in a clinical specimen, using the virus-specific primers and enzymatic nucleic acid amplification; hybridization of amplified target sequences, if present, with one or more Epstein-Barr virus-specific oligonucleotide probes which are labeled with a detectable moiety; and detection of the detectable moiety of labeled oligonucleotide probe hybridized to amplified target sequences of Epstein-Barr virus DNA.

The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.

Disclosed is a non-invasive method for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer by detecting and / or quantifying EBV associated nucleic acid fragments in a urine sample from an individual. Kits for diagnosis, prognosis or monitoring of cancer are also disclosed.

The present inventors introduced mRNAs for the Epstein-Barr virus proteins LMP1 and EBNA1 into antigen-presenting cells, and as a result, demonstrated that the cells induced Epstein-Barr virus-specific cytotoxic T cells. The present inventors also demonstrated that the cytotoxic T cells recognized epitope peptides presented via HLA-A*0206, HLA-Cw*0303, or HLA-Cw*0304, inhibited the outgrowth of Epstein-Barr virus-infected B cells, and lysed Epstein-Barr virus-infected NK lymphomas and NK cells.

Methods and composition for providing induced pluripotent stem (iPS) cells are provided. For example, in certain aspects methods including reprogramming B lymphocytes transformed by episomal vectors such as Epstein-Barr virus-based vectors are described. Furthermore, the invention provides induced pluripotent stem cells essentially free of exogenous elements and having B cell immunoglobin variable region rearrangement.

The present invention provides cytotoxic Epstein-Barr virus (EBV) T-cell epitopes derived from EBV structural antigens. Preferred epitopes include YLLEMLWRL (SEQ ID NO:1), YFLEILWGL (SEQ ID NO:32), YLLEILWRL (SEQ ID NO:33), YLQQNWWTL (SEQ ID NO:6), LLLALLFWL (SEQ ID NO:2), LLVDLLWLL (SEQ ID NO:3), LLLIALWNL (SEQ ID NO:4), WLLLFLAIL (SEQ ID NO:5), TLLVDLLWL (SEQ ID NO:7), LLWLLLFLA (SEQ ID NO:8), ILLIIALYL (SEQ ID NO:9), VLFIFGCLL (SEQ ID NO:10), RLGATIWQL (SEQ ID NO:11), ILYFIAFAL (SEQ ID NO:15), SLVIVTTFV (SEQ ID NO:17), LMIIPLINV (SEQ ID NO:20), TLFIGSHVV (SEQ ID NO:24), LIPETVPYI (SEQ ID NO:26), VLQWASLAV (SEQ ID NO:27) and QLTPHTKAV (SEQ ID NO:29). The present invention also provides methods of treating or preventing EBV infection in subjects which involve administration of EBV cytotoxic T-cell epitopes.

The invention belongs to the field of medicines and particularly relates to a new application of an iridoid glycoside compound, genipin-1-[beta]-D-gentiobioside, and a composition composed by compounding the genipin-1-[beta]-Dgentiobioside with other components as effective components for preparing antiviral drugs, antibacterial drugs, fever alleviating drugs, inflammation resistant drugs and anti-oxidizing drugs. The iridoid glycoside compound and the composition can be used for treating acute respiratory infection, flu, pneumonia, viral hepatitis type B, herpes zoster, herpes viral keratitis, viral myocarditis, Epstein-Barr virus infection, retrovirus infectious diseases and bacterial infectious diseases.

The present invention presents a method of preventing vertical transmission of an infectious disease comprising: (a) applying a photosensitizing composition to host tissues of birth canal of a mother during the intrapartum period; and (b) applying light to the host tissues after the step (a) at a wavelength absorbed by the photosensitizing composition so as to inhibit or eliminate infectious disease microorganisms that come into contact with the host tissues. The infectious disease may be caused by human immunodeficiency virus type 1, hepatitis B virus, hepatitis C virus, Group B Streptococcus, cytomegalovirus, Listeria monocytogenes, Chiamydia trachomatis, Escherichia coli, herpes simplex virus, Epstein-Barr virus, Toxoplasma gondii, human papilloma virus, and Candida.

The present invention relates to the identification of a subunit vaccine to prevent or treat infection of Epstein Barr Virus. In particular, EBNA-1 was identified as a vaccine antigen. In a specific embodiment, a purified protein corresponding to EBNA-1 elicited a strong CD4+ T cell response. The responsive CD4+ T cell are primarily TH1 in function. EBNA-1 is an attractive candidate for a protective vaccine against EBV, and for immunotherapy of EBV infection and neoplasms, particularly with dendritic cells charged with EBNA-1.

The invention provides a herpes virus EBV (Epstein-Barr Virus) detection kit. The kit comprises a nucleic acid releasing agent and PCR (polymerase chain reaction) reaction solution, wherein the nucleic acid releasing agent comprises 0.01-0.5 mM / L of surfactin, 20-300 mM / L of potassium chloride, 0.01-2% of sodium dodecyl sulphate and 0.05-1% of ethanol; and the PCR reaction solution comprises an upstream primer and a downstream primer used for target polynucleotide amplification, and a probe used for target polynucleotide detection. The detection result of the method for releasing nucleic acid by the nucleic acid releasing agent in the kit disclosed by the invention has no obvious difference with the detection result of a boiling method, a strong protein denaturing agent is used during nucleic acid extraction in the kit disclosed by the invention for rapidly breaking the coat protein structure of a pathogen and releasing the nucleic acid of the pathogen, and release and extraction for DNA (deoxyribonucleic acid) can be rapidly finished without heating; the sensitivity of the EBV detection of the kit disclosed by the invention can achieve 400 copies / ml, and the quantitative linear range is 400-4.00E+09 copies / ml; by applying the kit, rapid and accurate detection can be performed on EBV-DNA in the unknown samples of blood plasma, throat swab, peripheral blood and the like, and reliable experimental basis is provided for diagnosing EBV infection.

The invention relates to a kit for quantitative detection of an Epstein-Barr virus (EBV) nucleic acid by using a fluorescent polymerase chain reaction (PCR) technology. A pair of primers is used for amplifying an EBV specific nucleic acid sequence and EBVDNA is quantitatively detected through a fluorescence probe and meanwhile, an internal reference DNA is detected by using a human endogenous gene specificity primer and the fluorescence probe. By adopting the kit, existence of the EBV and internal reference nucleic acid is simultaneously detected by a single-tube double-wavelength fluorescent PCR technology, the EBVDNA in whole blood, plasma and a nasopharyngeal secretion sample can be quantitatively detected, and the whether a PCR inhibitor or template loss caused by a misoperation in detection exists in the sample is judged by the detection result of the internal reference nucleic acid. Thus, the kit is simple, convenient and fast in operation, can provide sensitive and accurate quantitative result, and can be widely applied to quantitative detection of clinical EBV virus infection.

The present invention relates to a vaccine for the treatment or prevention of an EBV-associated disease in a subject, wherein said vaccine comprises a synthetic polypeptide comprising a plurality of different segments of at least one parent EBV polypeptide, and wherein the segments are linked together in a different relationship relative to their linkage in the at least one parent EBV polypeptide.

Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease. Cells infected with latent virus may also encourage autoimmunity. Based on the understanding that reactivation or latency are important to produce or sustain autoimmunity, then therapies directed against Epstein-Barr virus will also be effective therapies for the autoimmune manifestations of disease for which Epstein-Barr virus is responsible.

Processes vectors and engineered cell lines for large-scale transfection and protein production in mammalian cells, especially Chinese Hamster Ovary (CHO) cells are described in which transfection efficiencies are realized through the use of a single vector system, the use of functional oriP sequences in all plasmids, the use of codon-optimized Epstein-Barr virus nuclear antigen-1 (EBNA1) constructs the use of a fusion protein between a truncated Epstein-Barr virus nuclear antigenen-1c (EBNA1c) protein and a herpes simplex virus protein VP16, the use of a 40 kDa fully deacetylated poly(ethylenimine) as a transfection reagent, the use of co-expression of a fibroblast growth factor (FGF) and / or the use of protein kinase B to potentiate heterologous gene expression enhancement by valproic acid (VPA).

The invention discloses a molecular target hsa-miR203 for diagnosing and treating nasopharyngeal cancer related with Epstein-Barr virus (EBV) infection and application thereof. The microRNA can accurately reflect the conditions of retention and loss of EBV viruses in cells and tissues, and further can be used for diagnosing the nasopharyngeal cancer related with the EBV infection; and meanwhile, target genes E2F3, CCNG1 and the like controlled by the hsa-miR203 obviously inhibit the proliferation and conversion capacities of the cells, so the hsa-miR203 can be used for treating the nasopharyngeal cancer related with the EBV infection. Therefore, the hsa-miR203 has important scientific research theory and clinical application value, and provides new clue and proof for diagnosis, treatment or prognosis of EBV related tumors.

The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1 ) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1 ) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention.

The present invention provides a cytotoxic T-cell (cytotoxic T lymphocyte, abbreviated hereinafter as CTL) epitope peptide specific to the Epstein-Barr virus (described hereinafter as EBV), a vaccinefor treating or preventing EBV infection or EBV-positive cancer using this peptide, a passive immunotherapeutic agent for EBV, and a method for assaying CTL specific to EBV. The present invention alsoprovides an HLA-A*24:02-restricted epitope peptide comprising an IYTEVRELV sequence (SEQ ID NO: 43) from a cytoskeleton-associated protein (cytoskeleton-associated protein 4: CKAP4 hereinafter, alsoknown as: CLIMP-63, ERGIC-63, P63). The peptide-specific cytotoxic T-cells (CTL hereinafter) can attack malignant tumor cells that express a high level of CKAP4.

The invention discloses a treble real-time fluorescence quantitative polymerase chain reaction (PCR) method for simultaneously detecting an epstein-barr virus (EBV), a polyma virus (BKV) and a cytomegaloviruses (CMV) of people and a kit, which belong to medical molecular biological detection techniques. Three sets of primers and probes of the three viruses, which are designed by self, are adoptedto simultaneously detect a specimen to be detected. Experiments show that through adopting the three sets of probes and primers to simultaneously amplify a template to be detected or a manually-configured verification standard substance, the stocks of the three viruses in the specimen can be reflected peculiarly and correctly, and the three viruses cannot interfere with one another.

The invention discloses an application of baicalein to the preparation of a drug for preventing and / or treating nasopharyngeal carcinoma. The application firstly proves that baicalein can remarkably inhibit a viral protein EBNA1 on which an Epstein-Barr virus exists, and a cell can become a normal cell due to tumor virus loss caused by overlow existing quantity of the protein in the cell. Baicalein can be favorably used for treating precancerous lesion, the conversion of severe rhinitis to nasopharyngeal carcinoma is effectively stopped, and the application has important significance for treating the precancerous lesion of nasopharyngeal carcinoma and reducing the occurrence rate and fatality rate of nasopharyngeal carcinoma.

The invention relates to a quantitative fluorescent multiplex PCR test kit for Epstein-Barr virus, and the kit comprises the following reagents: a, specific primer pairs for amplifying mutations of key target genes in the Epstein-Barr virus; and b, specific probes for the mutations of key target genes in the Epstein-Barr virus, wherein the mutations are P-thr, V-val and V-leu in the coding region of EBNA-1 gene, promoters Cp, Fp and Zp of the EBNA-1 gene, and XhoI-loss, 30bp Deletion and Ser 366 Thr of LMP1 gene. The test kit is advantageous in that: the aim of precise prediction of the risk of nasopharyngeal carcinoma in high risk population can be achieved; the main carcinogenic mutations can be well known for the combination of population screening and population intervention for nasopharyngeal carcinoma; and the kit has the advantages of high in sensitivity, fast in test, and low in cost, having broad market prospect.

The present invention relates to a vaccine comprising a particle, said particle comprising (i) at least one Epstein-Barr virus (EBV) structural polypeptide, (ii) at least one EBV lytic polypeptide, (iii) membrane lipids, said particle being devoid of EBV DNA, wherein (a) the B-cell transformation capacity of one or more EBV polypeptides required for B-cell transformation as comprised in said particle is disabled while their immunogenicity is maintained; and / or (b) said particle is devoid of one or more EBV polypeptides required for B-cell transformation. Furthermore, the invention relates to a method for generating a particle, to a cell obtained in the method of the invention, a kit comprising the vaccine or the particle generated according to the method of the invention. Also, the invention relates to the use of the vaccine or the particle generated according to the method of the invention for generating CD8+ cells specific for an EBV antigen.

An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and / or Epstein-Barr virus antigens.

The invention relates to the preparation and application of EB virus latent membrane protein 2B cell epitope recombinant protein. The invention discloses three B cell epitopes screened on the basis of full-length Epstein-Barr virus latent membrane protein 2. The invention also discloses the coding nucleotide and amino acid sequences of the B cell epitope. The invention also discloses the use of the B cell epitope in preventing, treating and diagnosing Epstein-Barr virus infection and related diseases. The protein of the invention has strong immunogenicity and antigenicity, and has good application prospect.

The invention provides a peripheral blood-based LCL-NK cell co-culture method, whichcomprises the following steps: preparing and obtaining the PBMC from the peripheral blood, and preparing the LCL cells from the PBMC, wherein the LCL cells are obtained by culturing PBMC (peripheral blood mononuclear cells) in supernate containing EBV (electron barr virus); the EBV supernate is obtained by carrying out culture passage on B958 cells, then carrying out starvation lysis and then separating; and co-culturing the cells in a culture system formed by PBMC, LCL cells, cell factors and a culture solution. According to the culture method provided by the scheme, the purity of a cell product is effectively improved, and the culture efficiency, the NK cell killing property and the like are remarkably improved.

Epstein-Barr virus (EBV) specific polypeptides consisting of a series of one to 1000 peptide units selected from the group consisting of peptide units Φ, Γ, Δ and Ω, wherein Φ is 25 amino acids or less and has the formula (αETFTETWNRFITHTEβ) (SEQ ID NO:1), Γ is 25 amino acids or less and has the formula (αGMLEASEGLDGWIHQβ) (SEQ ID NO:2), Δ is 25 amino acids or less and has the formula (αHQQGGWSTLIEDNIβ) (SEQ ID NO:3), Ω is 25 amino acids or less and has the formula (αKQKHPKKVKQAFNPLβ) (SEQ ID NO:4), α and β are each independently from 0 to 5 naturally occurring amino acids, and the polypeptide is capable of binding antibody in a specimen from an individual with Epstein-Barr virus (EBV)-associated disease are disclosed. Also disclosed are the use of these polypeptides for the production of polypeptide-specific antibodies and the diagnosis and treatment of EBV-associated disease.

The present invention provides Epstein-Barr virus (EBV)-negative NK cell lines. The NK cell lines of the present invention are useful for screening factors associated with the proliferation and expression functions of NK cells and to discover factors produced by the NK cells. In addition, the cell lines are immortalized despite the fact that they are EBV-negative. Thus, unknown mechanisms of oncogenesis may be elucidated through an understanding of the mechanisms underlying the immortalization of the cell lines of the present invention.

The invention provides a method for identifying lymphocyte subpopulations infected by an EB (epstein-barr) virus and a proportion of injected cells in the lymphocyte subpopulations and application ofthe method, and relates to the technical field of medical test. According to the method, a probe is mixed with a mononuclear cell extracted from preprocessed peripheral blood, and after hybridization,a flow cytometry measurement method is adopted to acquire and analyze to identify the lymphocyte subpopulations infected by the EB virus and the proportion of the injected cells in the lymphocyte subpopulations. The method has the advantages that the type of cells infected by the EBV (epstein-barr virus) can be found out accurately, the proportion of the infected cells in the lymphocyte subpopulations can be found out, according to the type of the cells infected by the EBV and the proportion of the infected cells, a targeted therapeutic schedule can be beneficially made to effectively and accurately treat diseases caused by EBV injection, and accordingly the method plays important roles in implement of accurate therapy and prognosis improvement of a patient.